诺华将斥资至多17亿美元收购生物技术公司Regulus Therapeutics

Core Viewpoint - Novartis has announced an agreement to acquire the biotechnology company Regulus Therapeutics for up to $1.7 billion, which includes an $800 million upfront payment and potential additional payments of up to $900 million upon achieving future regulatory milestones [1] Group 1: Acquisition Details - The total potential value of the acquisition is $1.7 billion, consisting of an $800 million upfront payment and up to $900 million contingent on regulatory milestones [1] - The transaction is expected to be completed in the second half of this year [1] Group 2: Company Focus - Regulus Therapeutics is focused on developing microRNA therapies, particularly targeting autosomal dominant polycystic kidney disease (ADPKD) [1]